CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023.

加利福尼亚州卡尔弗市（商业新闻短讯）--临床阶段免疫治疗公司ImmunityBio，Inc.（纳斯达克：IBRX）（“ImmunityBio”或“公司”）今天宣布，Oberland Capital向该公司提供高达3.2亿美元的特许权使用费融资和股权投资，2023年12月29日收盘时收到2.1亿美元的总收益。

The additional capital provides significant financial resources for the Company to accelerate its commercialization efforts in anticipation of a potential regulatory approval, as well as to expand its pipeline within the broader urological cancer space. The proceeds will also be used to fund ongoing business operations and clinical trials expanding N-803 (Anktiva®) indications into multiple solid tumors..

额外的资金为该公司提供了重要的财务资源，以加速其商业化努力，以获得潜在的监管批准，并在更广泛的泌尿系统癌症领域扩大其管道。收益还将用于资助正在进行的业务运营和将N-803（Anktiva®）适应症扩展到多种实体瘤的临床试验。。

ImmunityBio’s commercialization efforts are in anticipation of potential U.S. Food and Drug Administration (“FDA”) approval of Anktiva in combination with Bacillus Calmette-Guérin (“BCG”) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (“NMIBC”) with carcinoma in situ (CIS) with or without Ta or T1 disease.

ImmunityBio的商业化努力预计美国食品和药物管理局（FDA）可能会批准Anktiva联合卡介苗（BCG）治疗卡介苗无反应性非肌层浸润性膀胱癌（NMIBC）伴原位癌（CIS）伴或不伴Ta或T1疾病的患者。

The Company announced on October 23, 2023 that it had resubmitted its Biologics License Application (“BLA”) to the FDA, and announced on October 26, 2023 that the FDA had set a user fee goal date (PDUFA date) for the BLA resubmission of April 23, 2024. The Company’s pipeline is based on broad immunotherapy and cell therapy platforms that are designed to attack cancer and infectious pathogens by activating both the innate and adaptive branches of the immune system in an orchestrated manner..

该公司于2023年10月23日宣布，已向FDA重新提交其生物制剂许可证申请（“BLA”），并于2023年10月26日宣布，FDA已将BLA重新提交的用户费用目标日期（PDUFA日期）设定为2024年4月23日。该公司的产品线基于广泛的免疫疗法和细胞疗法平台，旨在通过以协调的方式激活免疫系统的先天和适应性分支来攻击癌症和传染性病原体。。

“This transaction raises significant capital for the Company to support important growth plans, yet with limited equity dilution and with a cap on total payments tied to the initial investment,” said Richard Adcock, Chief Executive Officer and President of ImmunityBio. “Besides providing a capital source at a key inflection point for ImmunityBio, this investment demonstrates strong confidence by Oberland Capital in our future, and in particular in the potential value of Anktiva in bladder cancer, as well as the direction of our clinical pipeline.”.

ImmunityBio首席执行官兼总裁理查德·阿德科克（Richard Adcock）表示：“这项交易为公司筹集了大量资金，以支持重要的增长计划，但股权稀释程度有限，并且对与初始投资相关的总付款有上限。”。“除了在ImmunityBio的关键转折点提供资金来源外，这项投资还显示了Oberland capital对我们未来的强大信心，特别是Anktiva在膀胱癌中的潜在价值，以及我们临床渠道的方向。”。

“We are excited to partner with ImmunityBio on the potential launch of Anktiva in the treatment of bladder cancer,” said Andrew Rubinstein, Managing Partner at Oberland Capital. “This investment aligns with our strategy of investing in near-commercial stage biopharmaceutical companies with highly differentiated products and deep clinical pipelines.”.

Oberland Capital管理合伙人安德鲁·鲁宾斯坦（AndrewRubinstein）表示：“我们很高兴与ImmunityBio合作，开发Anktiva治疗膀胱癌的潜在产品。”。“这项投资符合我们投资具有高度差异化产品和深度临床渠道的近商业阶段生物制药公司的战略。”。

The investment from Oberland Capital takes the form of a $300 million Revenue Interest Purchase Agreement (“RIPA”) that is non-dilutive to current investors, of which $200 million was funded at closing, and $100 million is to be funded contingent upon FDA approval of the Company’s BLA for Anktiva in combination with BCG for NMIBC, and subject to other terms and conditions as set forth in the RIPA.

Oberland Capital的投资采取了3亿美元收入利息购买协议（“RIPA”）的形式，该协议对当前投资者不具稀释性，其中2亿美元在交割时获得资助，1亿美元的资助将取决于FDA批准该公司的BLA为Anktiva，BCG为NMIBC，并遵守RIPA中规定的其他条款和条件。

Under the terms of the RIPA, Oberland Capital will have a right to receive initially tiered single-digit royalty payments on net sales of the Company’s products, which are capped at a multiple of their investment. In addition, the Company has entered into a purchase agreement with Oberland Capital for the private placement of 2,432,894 shares issued at closing, representing $10 million of gross proceeds based on the trailing 30-trading days VWAP.

根据RIPA的条款，Oberland Capital将有权获得公司产品净销售额的初始分层单位数字版税，该版税上限为其投资的倍数。此外，该公司已与奥伯兰资本（Oberland Capital）签订了一份购买协议，在收盘时私募发行2432894股股票，根据VWAP过去30个交易日的计算，总收益为1000万美元。

Oberland Capital has also an option to purchase an additional $10 million of common stock at a future date..

Oberland Capital还有权在未来购买额外1000万美元的普通股。。

In connection with the RIPA, the Company and Nant Capital entered into amendments to extend the maturity dates of certain existing promissory notes with an aggregate principal amount of approximately $505 million from December 31, 2024 to December 31, 2025, and to allow Nant Capital to convert up to an aggregate of $380 million of principal, plus accrued and unpaid interest, into shares of common stock at a price per share equal to a 75% premium to the closing market price on January 3, 2024.

就RIPA而言，公司和Nant Capital签订了修正案，将某些本金总额约为5.05亿美元的现有本票的到期日从2024年12月31日延长至2025年12月31日，并允许Nant Capital将本金总额加上应计和未付利息转换为3.8亿美元，每股价格相当于2024年1月3日收盘市价的75%溢价。

Nant Capital and the RIPA Purchaser Agent also concurrently entered into a Subordination Agreement, pursuant to which the Notes were subordinated to the Company’s obligations to the Purchasers under the RIPA..

Nant Capital和RIPA买方代理也同时签订了从属协议，根据该协议，票据从属于公司在RIPA下对买方的义务。。

Jefferies LLC acted as exclusive financial advisor to the Company on the transaction.

Jefferies LLC担任该公司在该交易中的独家财务顾问。

About ImmunityBio

关于ImmunityBio

ImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease.

ImmunityBio是一家垂直整合的临床阶段生物技术公司，开发下一代疗法和疫苗，增强自然免疫系统，战胜癌症和传染病。该公司的一系列免疫治疗和细胞治疗平台，单独或共同推动和维持免疫反应，目标是创造持久和安全的疾病防护。

ImmunityBio is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that ImmunityBio believes sharply reduce or eliminates the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases..

ImmunityBio正在将其科学和平台应用于治疗癌症，包括开发潜在的癌症疫苗，以及开发ImmunityBio认为可以大大减少或消除标准大剂量化疗需求的免疫疗法和细胞疗法。这些平台及其相关的候选产品旨在比当前的肿瘤学和传染病护理标准更有效，更容易获得和管理。。

N-803 is investigational. Safety and efficacy have not been established by any Health Authority or Agency, including the FDA.

N-803是研究性的。包括FDA在内的任何卫生当局或机构都没有确定安全性和有效性。

For more information, please visit https://ir.immunitybio.com

有关更多信息，请访问https://ir.immunitybio.com

About Oberland Capital

关于Oberland Capital

Oberland Capital is a private investment firm formed in 2013 with assets under management of approximately $3.5 billion, focused exclusively on investing in the global healthcare industry and specializing in flexible investment structures customized to meet the specific needs of its transaction partners.

Oberland Capital是一家成立于2013年的私人投资公司，管理资产约35亿美元，专注于投资全球医疗保健行业，并专注于定制灵活的投资结构，以满足其交易伙伴的特定需求。

Oberland Capital’s broad suite of financing solutions includes monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investments in traditional debt and equity. With a combination of deep industry knowledge and extensive structured finance experience, the Oberland Capital team has a history of creating value for its transaction partners..

奥伯兰资本（Oberland Capital）广泛的融资解决方案包括版税流货币化、未来产品收入的获取、基于项目的融资结构的创建以及对传统债务和股权的投资。凭借深厚的行业知识和丰富的结构性金融经验，Oberland Capital团队有着为交易伙伴创造价值的历史。。

For more information, please visit www.oberlandcapital.com or contact Johnna Schifilliti at (212) 257-5850.

欲了解更多信息，请访问www.oberlandcapital.com或致电（212）257-5850联系Johnna Schifilliti。

Forward Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the financing transactions described herein and use of proceeds to be received from such financing, the ultimate amount of proceeds expected to be received, the regulatory review process and timing thereof, ImmunityBio’s commercialization strategy for N-803, and ImmunityBio’s pipeline and development of therapeutics for cancers and infectious diseases, among others.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明，例如有关本文所述融资交易和融资收益使用、预期收益的最终金额、监管审查过程及其时间安排的声明，ImmunityBio针对N-803的商业化战略，以及ImmunityBio的管道和癌症和传染病治疗药物的开发等。

While ImmunityBio believes the BLA resubmission addresses the issues identified in the FDA’s complete response letter, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “seeks,” “should,” “will,” “strategy,” and variations of such words or similar expressions.

虽然ImmunityBio认为BLA重新提交解决了FDA完整回复信中确定的问题，但不能保证FDA最终会同意这些问题已经成功解决。本新闻稿中不属于历史事实声明的声明被视为前瞻性声明，通常通过使用诸如“预期”，“相信”，“继续”，“目标”，“可能”，“估计”，“预定”，“预期”，“打算”，“可能”，“计划”，“潜在”，“预测”，“指示”，“项目”，“寻求”，“应该”，“将会”，“策略”等单词或类似表达的变体来识别。

Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio.

关于我们临床前和临床试验的过去表现，努力或结果的陈述，可以做出推论或假设，也可以是前瞻性的陈述，并不表示未来的表现或结果。前瞻性陈述既不是预测、承诺也不是保证，而是基于ImmunityBio管理层目前的信念以及ImmunityBio做出的假设和目前可获得的信息。

Such information may be limited or incomplete, and ImmunityBio’s statements should not be read to indicate that it has conducted a .

这些信息可能是有限的或不完整的，不应阅读ImmunityBio的声明来表明它已经进行了。